Immunotherapy News and Research

Latest Immunotherapy News and Research

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.

8 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports.

7 Dec 2014

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma.

4 Dec 2014

$TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease$

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease.

4 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation.

2 Dec 2014

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study led by researchers at Dana-Farber Cancer Institute and the Yale University School of Medicine.

28 Nov 2014

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer Research UK to carry out a research study into the treatment of older patients with mantle cell lymphoma.

27 Nov 2014

Researchers discover why advanced melanoma patients respond to pembrolizumab drug

Work supported by the Stand Up To Cance - Cancer Research Institute - Immunology Translational Research Dream Team, launched in 2012 to focus on how the patient's own immune system can be harnessed to treat some cancers have pioneered an approach to predict why advanced melanoma patients respond to a new life-saving melanoma drug.

27 Nov 2014

New research brings personalized cancer vaccine approach one step closer to reality

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Novel targeted therapies and treatment combinations for leukemia

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Novel treatments show promising results in patients with different hematologic disorders

Study: Key protein may help prevent tumor growth, promote wound healing

Innovative cell therapy shows highly promising results in pediatric patients with ALL

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Oncologists examine efficacy of rose bengal against cancer

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Experimental drug works best when patients' immune cells surrounding tumors express PD-L1

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Researchers discover why advanced melanoma patients respond to pembrolizumab drug

New research brings personalized cancer vaccine approach one step closer to reality

Scientists make breakthrough in developing new treatment for advanced bladder cancer

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in